Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A new analysis of information from the Surveillance, Epidemiology and End Results (SEER) database suggests that the “hazard” for prostate cancer-specific mortality after radical prostatectomy is very low but that it does increase in a continuous manner for at least 15 years post-treatment.
Filed under: Living with Prostate Cancer, Management | Tagged: hazard, mortality, PCSM, prostate cancer-specific, radical prostatectomy, surgery | 6 Comments »
A fascinating new paper based on data from the Prostate Cancer DataBase Sweden provides important insight into the consequences of delayed diagnosis and potential under-treatment of men who are diagnosed with locally advanced prostate cancer.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: delayed, Diagnosis, locally advanced, mortality, prostate cancer-specific | 14 Comments »
An article in Progrès en urologie states that the prostate cancer-specific mortality rate in France has been dropping by 2.5 percent per year.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: France, mortality, prostate cancer-specific | 1 Comment »
As a follow-up to our earlier post on this topic, we have now identified the original media release issued by Kings College London and the UK’s National National Cancer Intelligence Network (NCIN) on which today’s article in The Daily Telegraph (and other media) was based. That article clearly stated that up to 49 percent of [...]
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: mortality, prostate cancer-specific, UK, United Kingdom | 11 Comments »
A report in The Daily Telegraph today states that “experts at King’s College London have now found the proportion of men with prostate cancer who actually die from it to be higher than previously thought.” Supposedly, the new research finding is that for 49 percent of 20,000 men diagnosed between 1997 and 2007 “prostate cancer [...]
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: mortality, prostate cancer-specific, UK, United Kingdom | 7 Comments »
With the failure of Combidex (ferumoxtran-10) to achieve FDA approval as an imaging agent for lymph node-positive prostate cancer and the recognized limitations of the ProstaScint (capromab pendetide) scan, there is a widely acknowledged need for a much more specific and accurate prostate cancer imaging agent than anything currently available.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Endocyte, imaging, prostate cancer-specific, Purdue | Leave a Comment »
A new analysis of information from the Swedish national prostate cancer registry database and the Swedish cause of death register has confirmed the importance of aggressive, curative treatment of men with locally advanced prostate cancer.
Filed under: Living with Prostate Cancer, Management | Tagged: locally advanced, mortality, prostate cancer-specific, Sweden | 1 Comment »
One of the most complicated questions in dealing with prostate cancer is correctly assessing whether men who are known to have had prostate cancer actually died of their prostate cancer or simply with it, especially among men of more advanced age or with co-morbid conditions. In other words, “What do prostate cancer patients die of?”
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: cause, death, mortality, prostate cancer-specific, risk | 9 Comments »
For several years we have been able to use the Kattan nomograms to project 5-, 7-, and 10-year recurrence-free survival before and after radical prostatectomy for localized prostate cancer, based on the patient’s age, stage, Gleason score, and other relevant data (associated with biopsy or surgical findings, as appropriate).
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: 15-year, Kattan, mortality, nomogram, PCSM, prediction, projection, prostate cancer-specific, radical prostatectomy, surgery | 36 Comments »
The recently revised National Comprehensive Cancer Network guidelines for the management of prostate cancer emphasize the importance of life expectancy in estimating individual patient risk of prostate cancer mortality — particularly for those patients with low- and very low-risk disease.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: life expectancy, mortality, prostate cancer-specific | 8 Comments »
An article just published by a highly respected group of specialists in the Journal of Clinical Oncology adds emphasis to the problem faced by patients newly diagnosed with low- or intermediate-risk localized prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: mortality, nomogram, PCSM, prostate cancer-specific, radical prostatectomy | 7 Comments »
Two studies presented at the AUA on Monday dealt with the mortality rates of men diagnosed with prostate cancer and treated with differing types of first line therapy.
Filed under: Management, Treatment, Uncategorized | Tagged: mortality, overall, prostate cancer-specific | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site